[go: up one dir, main page]

JP2002145777A - アラキドン酸誘発皮膚疾患治療剤 - Google Patents

アラキドン酸誘発皮膚疾患治療剤

Info

Publication number
JP2002145777A
JP2002145777A JP2000337359A JP2000337359A JP2002145777A JP 2002145777 A JP2002145777 A JP 2002145777A JP 2000337359 A JP2000337359 A JP 2000337359A JP 2000337359 A JP2000337359 A JP 2000337359A JP 2002145777 A JP2002145777 A JP 2002145777A
Authority
JP
Japan
Prior art keywords
acid
arachidonic acid
skin diseases
cell carcinoma
acid metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000337359A
Other languages
English (en)
Japanese (ja)
Inventor
Kosei Watanabe
孝正 渡辺
Masako Uchida
昌子 内田
Masazumi Terajima
寺島　　正純
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eneos Corp
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Japan Energy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Japan Energy Corp filed Critical Sumitomo Pharmaceuticals Co Ltd
Priority to JP2000337359A priority Critical patent/JP2002145777A/ja
Priority to PCT/JP2001/009575 priority patent/WO2002036592A1/fr
Priority to AU2002212695A priority patent/AU2002212695A1/en
Publication of JP2002145777A publication Critical patent/JP2002145777A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2000337359A 2000-11-06 2000-11-06 アラキドン酸誘発皮膚疾患治療剤 Pending JP2002145777A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000337359A JP2002145777A (ja) 2000-11-06 2000-11-06 アラキドン酸誘発皮膚疾患治療剤
PCT/JP2001/009575 WO2002036592A1 (fr) 2000-11-06 2001-10-31 Remedes aux maladies causees par l'acide arachidonique
AU2002212695A AU2002212695A1 (en) 2000-11-06 2001-10-31 Remedies for arachidonic acid-induced skin diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000337359A JP2002145777A (ja) 2000-11-06 2000-11-06 アラキドン酸誘発皮膚疾患治療剤

Publications (1)

Publication Number Publication Date
JP2002145777A true JP2002145777A (ja) 2002-05-22

Family

ID=18812759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000337359A Pending JP2002145777A (ja) 2000-11-06 2000-11-06 アラキドン酸誘発皮膚疾患治療剤

Country Status (3)

Country Link
JP (1) JP2002145777A (fr)
AU (1) AU2002212695A1 (fr)
WO (1) WO2002036592A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429848C2 (ru) * 2005-07-20 2011-09-27 Петер ФАЛЕНТ Композиции для лечения системного мастоцитоза

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
KR100962751B1 (ko) 2001-11-29 2010-06-09 쓰리엠 이노베이티브 프로퍼티즈 컴파니 면역 반응 변경제를 포함하는 제약 제제
CA2365732A1 (fr) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Etalonnages
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
BR0307788A (pt) 2002-02-22 2006-04-04 3M Innovative Properties Co método de redução e tratamento de imunossupressão induzida por uv-b
CN1674894A (zh) 2002-06-07 2005-09-28 3M创新有限公司 醚取代的咪唑并吡啶
EP2269632B1 (fr) 2002-08-15 2014-01-01 3M Innovative Properties Co. Compositions immunostimulatrices et procédés de stimulation d'une réponse immunitaire
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
JP2006513212A (ja) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー アリール／ヘタリール置換されたイミダゾキノリン
CA2511538C (fr) 2002-12-30 2013-11-26 3M Innovative Properties Company Complexes immunostimulants
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
WO2004075865A2 (fr) 2003-02-27 2004-09-10 3M Innovative Properties Company Modulation selective d'une activite biologique induite par le recepteur tlr
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
JP2006523212A (ja) 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー 皮膚病変の診断方法
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
MXPA05009694A (es) 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
CA2521682A1 (fr) 2003-04-10 2004-12-16 3M Innovative Properties Company Distribution de composes modifiant une reponse immunitaire au moyen de materiaux de support particulaires contenant du metal
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004110991A2 (fr) 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESSUS DE PREPARATION D'IMIDAZO[4,5-c]PYRIDINE-4-AMINES
WO2005016275A2 (fr) 2003-08-05 2005-02-24 3M Innovative Properties Company Preparations contenant un modificateur de la reponse immunitaire
CA2535117A1 (fr) 2003-08-12 2005-03-03 3M Innovative Properties Company Composes contenant une structure imidazo a substitution oxime
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005079195A2 (fr) 2003-10-03 2005-09-01 3M Innovative Properties Company Pyrazolopyridines et analogues de celles-ci
EP1673087B1 (fr) 2003-10-03 2015-05-13 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
CA2547020C (fr) * 2003-11-25 2014-03-25 3M Innovative Properties Company Derives de 1h-imidazo[4,5-c]pyridine-4-amine en tant que compose modificateur de la reponse immunitaire
US8778963B2 (en) 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005055932A2 (fr) 2003-12-02 2005-06-23 3M Innovative Properties Company Combinaisons therapeutiques et methodes faisant appel a des composes irm
CA2549216A1 (fr) 2003-12-04 2005-08-25 3M Innovative Properties Company Ethers cycliques imidazo substitues au sulfone
US7884207B2 (en) 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
ATE555786T1 (de) 2004-09-02 2012-05-15 3M Innovative Properties Co 1-alkoxy 1h-imidazo-ringsysteme und verfahren
JP2008511683A (ja) 2004-09-02 2008-04-17 スリーエム イノベイティブ プロパティズ カンパニー ２−アミノ１ｈ−イミダゾ環構造および方法
EP1844201B1 (fr) 2005-02-04 2016-08-24 3M Innovative Properties Company Formulations des gel aqueux contenant des modificateurs de reponse immunitaire
JP5122980B2 (ja) 2005-02-09 2013-01-16 スリーエム イノベイティブ プロパティズ カンパニー アルキルオキシ置換チアゾロキノリン類およびアルキルオキシ置換チアゾロナフチリデン類
EP1850849A2 (fr) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Methode d'induction preferentielle de la biosynthese d'interferon
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
EP3085373A1 (fr) 2006-02-22 2016-10-26 3M Innovative Properties Company Conjugués de modificateur de réponse immunitaire
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
SMT201700182T1 (it) 2010-08-17 2017-05-08 3M Innovative Properties Company Composizioni di composti modificanti la risposta immunitaria lipidati, formulazioni e metodi
EP3366311B1 (fr) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazoquinoléine-4-amines et conjugués obtenus à partir de celles-ci
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1998017279A1 (fr) * 1996-10-25 1998-04-30 Minnesota Mining And Manufacturing Company Composes modificateurs de la reponse immunitaire pour le traitement des maladies induites par les th2 ou associees
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
CZ20012446A3 (cs) * 1999-01-08 2002-01-16 3M Innovative Properties Company Farmaceutický prostředek pro léčbu onemocnění sliznice

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429848C2 (ru) * 2005-07-20 2011-09-27 Петер ФАЛЕНТ Композиции для лечения системного мастоцитоза

Also Published As

Publication number Publication date
WO2002036592A1 (fr) 2002-05-10
AU2002212695A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
JP2002145777A (ja) アラキドン酸誘発皮膚疾患治療剤
US11154533B2 (en) Topical compositions and methods for treating inflammatory skin diseases
RU2720204C1 (ru) Сублингвальная фармацевтическая композиция эдаравона и (+)-2-борнеола
JP2000247884A (ja) アラキドン酸誘発皮膚疾患治療剤
KR20070116632A (ko) 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
CA3097053A1 (fr) Composition pharmaceutique d'edaravone
AU2024266962A1 (en) Treatment of hand eczema
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
WO2020190072A1 (fr) Composition favorisant la cicatrisation des plaies cutanées ou la régénération de la peau, contenant du (r)-ginsénoside rg3 en tant que principe actif
WO2005034936A1 (fr) Utilisation de l-butylphtalide dans la fabrication de medicaments destines a la prevention et au traitement de l'infarctus cerebral
CN111346081B (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
JP2009196934A (ja) ニューキノロン系抗菌薬及び乳剤性基剤を含む医薬組成物
JPH1017478A (ja) 潰瘍性大腸炎の予防又は治療剤
CN104758304A (zh) 三七皂苷r1的医药用途
US10463643B2 (en) Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea
TWI397413B (zh) 那布扶林（ｎａｌｂｕｐｈｉｎｅ）新給藥途徑、新口服劑型及新使用劑量
KR20070059079A (ko) 경피 페로스피론 투여용 의약적 조성물
EP4470563A1 (fr) Thérapie et prévention innovantes pour supprimer les troubles liés au vieillissement, notamment la sarcopénie
JP2000256212A (ja) 良性間葉系腫瘍の治療剤
JP7520810B2 (ja) 医薬製剤
CN114652732B (zh) 白头翁皂苷b4在制备治疗阳痿药物中的应用
JP4477504B2 (ja) 鎮痒剤
JP7442820B2 (ja) びまん性胃癌の治療剤
JP2024158843A (ja) リドカインゲル製剤
TWI735658B (zh) 用於減少代謝症候群之組合物及其應用

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050720

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050720

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20051026